A cohort in the SPARK trial reported activity for the combination of sitravatinib and tislelizumab in locally recurrent or metastatic triple‑negative breast cancer. The multi‑cohort phase II single‑arm study evaluated the regimen’s anti‑tumor activity and safety in a hard‑to‑treat population. While single‑arm data require confirmation, the results add to interest in kinase‑checkpoint combinations for immune‑cold tumors and may inform potential registration strategies or combination development.